GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001593111 | Liver | HCC | nucleobase-containing compound transport | 150/7958 | 222/18723 | 3.17e-14 | 2.03e-12 | 150 |
GO:000599621 | Liver | HCC | monosaccharide metabolic process | 167/7958 | 257/18723 | 2.31e-13 | 1.25e-11 | 167 |
GO:001931821 | Liver | HCC | hexose metabolic process | 155/7958 | 237/18723 | 7.63e-13 | 3.90e-11 | 155 |
GO:000600621 | Liver | HCC | glucose metabolic process | 128/7958 | 196/18723 | 8.60e-11 | 3.06e-09 | 128 |
GO:006201222 | Liver | HCC | regulation of small molecule metabolic process | 190/7958 | 334/18723 | 6.77e-08 | 1.40e-06 | 190 |
GO:00463642 | Liver | HCC | monosaccharide biosynthetic process | 58/7958 | 82/18723 | 2.08e-07 | 3.75e-06 | 58 |
GO:000610921 | Liver | HCC | regulation of carbohydrate metabolic process | 109/7958 | 178/18723 | 3.36e-07 | 5.78e-06 | 109 |
GO:00193192 | Liver | HCC | hexose biosynthetic process | 54/7958 | 78/18723 | 1.61e-06 | 2.27e-05 | 54 |
GO:00109062 | Liver | HCC | regulation of glucose metabolic process | 76/7958 | 119/18723 | 2.03e-06 | 2.79e-05 | 76 |
GO:00060942 | Liver | HCC | gluconeogenesis | 52/7958 | 75/18723 | 2.34e-06 | 3.14e-05 | 52 |
GO:00106752 | Liver | HCC | regulation of cellular carbohydrate metabolic process | 88/7958 | 146/18723 | 1.08e-05 | 1.24e-04 | 88 |
GO:004426221 | Liver | HCC | cellular carbohydrate metabolic process | 153/7958 | 283/18723 | 5.27e-05 | 5.00e-04 | 153 |
GO:00160512 | Liver | HCC | carbohydrate biosynthetic process | 113/7958 | 202/18723 | 7.64e-05 | 6.83e-04 | 113 |
GO:1901264 | Liver | HCC | carbohydrate derivative transport | 48/7958 | 80/18723 | 1.19e-03 | 6.62e-03 | 48 |
GO:00061111 | Liver | HCC | regulation of gluconeogenesis | 31/7958 | 48/18723 | 1.66e-03 | 8.71e-03 | 31 |
GO:00432551 | Liver | HCC | regulation of carbohydrate biosynthetic process | 56/7958 | 97/18723 | 1.75e-03 | 9.11e-03 | 56 |
GO:0008643 | Liver | HCC | carbohydrate transport | 80/7958 | 152/18723 | 7.34e-03 | 2.92e-02 | 80 |
GO:0015931110 | Thyroid | PTC | nucleobase-containing compound transport | 120/5968 | 222/18723 | 5.45e-12 | 2.35e-10 | 120 |
GO:001931810 | Thyroid | PTC | hexose metabolic process | 108/5968 | 237/18723 | 6.42e-06 | 7.65e-05 | 108 |
GO:000599614 | Thyroid | PTC | monosaccharide metabolic process | 115/5968 | 257/18723 | 9.36e-06 | 1.05e-04 | 115 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC35B4 | SNV | Missense_Mutation | novel | c.450G>T | p.Glu150Asp | p.E150D | Q969S0 | protein_coding | tolerated(0.27) | benign(0.009) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC35B4 | SNV | Missense_Mutation | | c.446N>A | p.Ser149Asn | p.S149N | Q969S0 | protein_coding | tolerated(0.36) | benign(0) | TCGA-AN-A0AM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC35B4 | SNV | Missense_Mutation | | c.740T>C | p.Ile247Thr | p.I247T | Q969S0 | protein_coding | tolerated(0.06) | benign(0.001) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
SLC35B4 | SNV | Missense_Mutation | novel | c.520T>C | p.Ser174Pro | p.S174P | Q969S0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SLC35B4 | SNV | Missense_Mutation | rs762326247 | c.758N>A | p.Cys253Tyr | p.C253Y | Q969S0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
SLC35B4 | SNV | Missense_Mutation | rs374056103 | c.697G>A | p.Gly233Arg | p.G233R | Q969S0 | protein_coding | deleterious(0.01) | possibly_damaging(0.5) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC35B4 | SNV | Missense_Mutation | novel | c.735G>A | p.Met245Ile | p.M245I | Q969S0 | protein_coding | tolerated(0.48) | benign(0.003) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SLC35B4 | SNV | Missense_Mutation | rs759264873 | c.827G>A | p.Arg276His | p.R276H | Q969S0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
SLC35B4 | SNV | Missense_Mutation | novel | c.721T>C | p.Phe241Leu | p.F241L | Q969S0 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AX-A063-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC35B4 | SNV | Missense_Mutation | novel | c.494N>A | p.Gly165Glu | p.G165E | Q969S0 | protein_coding | deleterious(0.04) | benign(0.157) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |